A New 'Plug and Play' Method for Building Cyclotide-Based Peptide Drugs

The researchers developed a chemical synthesis strategy where bioactive peptide sequences are grafted onto a pre-formed acyclic cyclotide-like scaffold, rather than attempting to fold the entire modified cyclotide from scratch. They tested this approach with sequences known to be difficult to produce via conventional oxidative folding, including epitopes with extra disulfide bonds, and measured the resulting peptides' ability to bind and activate GPCRs.

Cyclotides are extremely stable peptides that resist digestion and could potentially be taken orally — a holy grail for peptide drug design. But engineering them to carry therapeutic payloads has been limited by the difficulty of folding modified sequences. This new modular approach removes that barrier, potentially opening the door to a much wider range of cyclotide-based drugs targeting GPCRs, which are involved in nearly every major disease area.

GPCRs are the targets of roughly 34% of all FDA-approved drugs, but most GPCR drugs are small molecules with off-target effects. Cyclotide scaffolds offer greater selectivity and oral bioavailability, but engineering them has been technically limited. This plug-and-play method could accelerate the development of a new class of orally active, highly selective peptide drugs for conditions from pain to metabolic disease.

This is a proof-of-concept laboratory study focused on chemical synthesis methodology. No in vivo testing or pharmacokinetic data were reported. The approach was demonstrated with a limited number of target sequences, and broader applicability across diverse epitopes and GPCR targets remains to be established. Long-term stability and manufacturability at scale were not addressed.